Endo International (ENDP) Tops Q2 EPS by 31c, Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Endo Reports Second-Quarter 2020 Financial Results
August 5, 2020 4:30 PM EDTRevenues decreased 2% to $688 million compared to prior year
On July 6, 2020, U.S. FDA approved Qwo (collagenase clostridium histolyticum-aaes), the first injectable treatment for cellulite
DUBLIN, Aug. 5, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the second quarter ended June 30, 2020.



